Since 1975, the prevalence of obesity has nearly tripled, being a major healthcare problem worldwide(1), urging the need for non-invasive treatment strategies. The gastrointestinal (GI) tract plays a crucial role in the regulation of eating behaviour via its ability to produce and secrete GI peptides upon food-derived triggers(Reference Verdich, Flint and Gutzwiller2–Reference Lieverse, Jansen and van de Zwan4).
In order for the GI tract to modulate eating behaviour, food constituents need to be sensed in the gut. It has been shown that intestinal infusion of macronutrients reduces food intake that is accompanied by the release of GI peptides, generally called the intestinal brake(Reference van Avesaat, Troost and Ripken5–Reference Shin, Ingram and McGill7), which is operable in a proximal to distal intestinal gradient(Reference Alleleyn, van Avesaat and Troost8).
Another way to perceive food constituents in the gut is via taste receptors, which are expressed throughout the entire GI tract(Reference van der Wielen, van Avesaat and de Wit9–Reference Bezencon, le Coutre and Damak11) and have been shown to trigger the release of GI peptides in vitro (Reference Sternini, Anselmi and Rozengurt12–Reference Geraedts, Troost and Saris15). Duodenal delivery of a tastant mixture containing non-energetic sweet, bitter and umami tastants resulted in significant decrease in food intake, without affecting systemic GI peptide levels(Reference van Avesaat, Troost and Ripken16). However, the proximal to distal gradient operable for macronutrients was not applicable to tastants(Reference Klaassen, Alleleyn and van Avesaat17).
Inhibition of food intake via taste receptors may occur via pathways different from those via nutrient receptors. It has been hypothesised that taste predicts the type of food that is ingested (i.e. bitter for toxic substances, umami for amino acids and sweet for carbohydrates)(Reference Breslin and Spector18). Since bitter taste is linked to toxic substances, subsequent food intake could be limited via an aversive reaction to bitter tastants. Currently, data on sole oral effects of (bitter) tastant delivery (i.e. without ingesting) on eating behaviour are lacking.
Besides endocrine signalling, the autonomic nervous system (ANS) plays a role in appetite signalling. Changes in the balance of ANS can occur prior to changes in GI peptide levels in the presence of a shift from hunger to satiety(Reference Nederkoorn, Smulders and Jansen19,Reference Mattes20) . Increased sympathetic tone is suggested to indicate satiation in humans(Reference Harthoorn and Dransfield21). In addition to aversive responses in reaction to bitter substances, bitter taste also exerts a strong sympathetic activation(Reference Pavli, Tassou and Nychas22). A simple, non-invasive method to measure ANS is heart rate variability (HRV), a physiological variation in time interval between consecutive heartbeats(23).
This study investigated the effects of oral- v. intragastric v. synchronous oral- and intragastric delivery of the bitter tastant quinine on eating behaviour in healthy subjects, with ad libitum food intake as primary outcome and HRV, appetite sensations and GI-complaints as secondary outcomes. We hypothesised that synchronous oral and intragastric delivery of quinine decreases food intake compared with placebo or delivery of quinine solely oral- or intragastric. Moreover, we expected that solely oral- or intragastric delivery of quinine would decrease food intake compared with placebo, albeit to a lesser extent than synchronous oral- and intragastric delivery of quinine. Finally, we expect oral delivery of quinine to decrease food intake to a greater extent than intragastric delivery of quinine.
Methods
This study was approved by the Medical Ethics Committee of the Maastricht University Medical Center+ (MUMC+), Maastricht, the Netherlands (ID METC163047), and performed in full accordance with the Declaration of Helsinki (latest amendment by the World Medic Association in 2013) and Dutch Regulations on Medical Research involving Human Subjects (WMO, 1998). The study was performed at the Maastricht University Campus Venlo from 17 August 2018 until 15 August 2019. This study was registered in the US National Library of Medicine (http://www.clinicaltrials.gov, ID NCT 03565133). All subjects gave written informed consent before screening.
Subjects
Healthy men and women were recruited by local advertisements. Inclusion criteria were age between 18 and 65 years, a BMI between 18 and 25 kg/m2, with a stable weight over the past 6 months (<5 % body weight change). Exclusion criteria were GI complaints, history of chronic or severe disease, use of medication influencing study endpoints within 14 d prior to testing, administration of investigational drugs which interfere with this study, major abdominal surgery, dieting, pregnancy or lactation, excessive alcohol consumption (>20 alcoholic consumptions per week), smoking and non-tasters of the bitter stimulus quinine.
Prior to testing, screening was performed where above-mentioned in- and exclusion criteria were checked and a taste perception test with quinine was performed. Subjects tasted quinine (0·5 mmol/l) and tap water blindly and had to indicate their sense of taste. Subjects had to correctly identify the bitter taste of the quinine sample in order to be eligible for the study. Furthermore, length and weight were measured to calculate BMI.
Study design
In this blinded randomised, placebo-controlled crossover study, subjects received a capsule containing quinine or placebo (cellulose, which is tasteless and odourless in itself(Reference Pavli, Tassou and Nychas22,Reference Burdock24) ) and subjects performed oral sham-feeding with quinine dissolved in tap water or placebo (tap water) on four test days separated by at least 1-week wash-out. An independent researcher not involved in execution of the study generated the randomisation list using www.sealedenvelope.com. On each test day, participants received one of the following interventions in random order: oral placebo and intragastric placebo (OPGP), oral quinine and intragastric placebo (OQGP), oral placebo and intragastric quinine (OPGQ), and oral quinine and intragastric quinine (OQGQ). Subjects and researchers were blinded for the containments of the capsule, but not for the substance used for oral sham feeding as subjects cannot be blinded for the taste of oral sham feeding intervention. Moreover, due to an evolutionary aversive reaction to tasting a bitter substance(Reference Steiner, Glaser and Hawilo25), subjects would involuntarily show whether oral sham feeding with tap water or with quinine dissolved in tap water is being performed. Therefore, the researcher could not be blinded for the oral sham condition.
Oral sham feeding
For oral sham feeding, 75 mg of quinine-hydrochloride (Arnold Suhr) was dissolved in 120 ml tap water. A magnetic stirrer was used to dissolve the quinine. As the placebo condition, 120 ml tap water were used. Sham feeding was performed by letting subjects take several sips (habitual size as if they would take a sip of a drink) out of one cup and letting them swish the contents around with closed mouth for 20–30 s before expectorating it in a different cup according to previously described protocols(Reference Just, Pau and Engel26,Reference Teff, Devine and Engelman27) . This induced 2–3 min of sensory stimulation.
Intragastric capsule
Capsules were manufactured by ‘Verenigde Apotheken Limburg (VAL) Bereidingsapotheek’. Gelatin capsules were filled with 75 mg quinine-hydrochloride and cellulose. As the placebo, capsules were filled with cellulose only. The capsules were indistinguishable in terms of appearance and weight. According to the VAL capsule, breakup time was <9 min (unpublished results). A dosage of 75 mg quinine-hydrochloride was used, as this aligns with previous research from our group(Reference van Avesaat, Troost and Ripken16,Reference Klaassen, Alleleyn and van Avesaat17) .
Protocol
On each test day, after an 8 h overnight fast, subjects arrived at 08.30 hours at the Maastricht University Campus Venlo. Subjects were instructed to consume the same habitual meal on the evening prior to testing. At t = −150 min, subjects consumed a standardised liquid breakfast meal (250 ml Goedemorgen drinkontbijt (Vifit, Friesland Campina); energy 649 kJ (155 kcal) per portion, 22 g carbohydrates, 8·5 g protein, and 2 g fat). At 150 min (at t = 0 min) after breakfast consumption, subjects ingested the capsule with 120 ml tap water and directly thereafter performed the oral sham feeding. Participants were not allowed to rinse their mouths after the sham feeding. Participants reported a persistent bitter taste in their mouth, although this was not quantified. At 50 min after the intervention (at t = 50), subjects received a standardised ad libitum lunch meal. During the test day, HRV measurements (at t = −150 min, t = −15 min, t = 5 min, and t = 35 min) were performed and visual analogue scale (VAS) scores for appetite sensations (t = −20 min, t = −10 min, t = 0 min, t = 10 min, t = 20 min, t = 30 min, t = 40 min, t = 50 min, and t = END) were collected. An overview of the timeline of the test days can be found in Fig. 1.
Timeline of the test day. A standardised breakfast was consumed at t = −150 min. At t = 0 min, participants ingested a capsule containing quinine or placebo and oral sham feeding with quinine dissolved in tap water or solely tap water was performed. At 50 min after the intervention, an ad libitum test meal was offered. Heart rate variability (HRV) measurements were performed, and visual analogue scales (VAS) scores for appetite sensations and gastrointestinal complaints were collected over the course of the test day. Endpoint of the study and last VAS scores varied per subject, depending on the duration of test meal intake.
Ad libitum test meal
Subjects received a standardised ad libitum lunch meal (Lasagna Bolognese (Plus supermarket); energy density per 100 g: 582 kJ (139 kcal); food constituents: 10·6 g carbohydrates, 8·1 g protein, and 6·7 g fat) 50 min (at t = 50 min) after the intervention. The test meal was offered in excess (a portion of 1 kg (5816 kJ (1390 kcal)), which is more than half of the recommended daily intake. No participant finished the entire portion), and subjects were instructed to eat until they felt satiated.
Visual analogue scales for appetite sensations and gastrointestinal complaints
Appetite sensations and GI complaints (e.g. satiety, hunger, stomach pain and nausea) were measured using VAS (0–100 mm) over the course of the test day. Subjects were asked to indicate on a line, anchored at the low end with the lowest intensity feelings, with opposing terms at the high end, which place on the scale best reflected their feeling at that moment(Reference Parker, Sturm and MacIntosh28).
Heart rate variability
Utilising only standard and unipolar leads, short time electrocardiogram records were obtained using computer electrocardiograph ‘Poly-Spectrum-8/E’ (Neurosoft®, version 5.3.1.0). Recordings of 5 min were performed after a resting period of at least 5 min. Measurements were performed in a semi-recumbent position in order to minimise ectopic activity. With a sampling frequency of 2 kHz, successive heartbeats or inter-beat intervals were determined and analysed according to HRV standards using ‘Poly-Spectrum-8’ (Neurosoft®, version 5.3.1.0) software(23). The power spectral analysis was performed with a fast Fourier transformation. Total power (0·01–0·40 Hz), high-frequency power (0·15–0·40 Hz), low-frequency power (0·04–0·15 Hz), and very low-frequency power (0·01–0·04 Hz) were calculated. For this study, heart rate and low-frequency:high-frequency ratio were investigated.
Statistical analyses
A sample size calculation was based on the difference in food intake after duodenal infusion of the bitter tastant quinine in comparison to food intake after duodenal infusion of placebo as reported by van Avesaat et al. (Reference van Avesaat, Troost and Ripken16). We anticipated the same magnitude for change comparing the combined oral and gastric administration v. placebo. Using a difference in means of 184 kJ (44 kcal), a standard deviation of difference of 356 kJ (85 kcal), a power of 80 %, and an α of 5 %, a total number of thirty-two subjects was needed.
Data were analysed using IBM SPSS Statistics 25 (IBM Corporation). Kolmogorov–Smirnov tests and a visual check of normality of the data were performed. The primary outcome of this study was food intake during an ad libitum lunch meal. Secondary outcomes were VAS scores for appetite sensations and GI complaints, and HRV measurements. Data are presented as mean values with their standard errors (unless specified otherwise).
Age, BMI and sex were calculated by descriptive statistics.
Food intake measurements were compared using an autoregressive (1) linear mixed model with intervention, test day and the interaction of intervention × test day as fixed factors. In case, no intervention × test day interaction was found, this factor was removed from the model to get the best model fit.
VAS scores for appetite sensations and GI complaints were compared using an autoregressive (1) linear mixed model with intervention, test day, time and the interactions of intervention × test day and time × intervention as fixed factors. In case no intervention × test day interaction was found, this factor was removed from the model to get the best model fit.
HRV measurements were compared using an autoregressive (1) linear mixed model with intervention, test day, time and the interactions of intervention × test day and time × intervention as fixed factors. In case no intervention × test day interaction was found, this factor was removed from the model to get the best model fit.
For all analyses, P < 0·05 was considered statistically significant. Whenever a main effect was found, Bonferroni correction for multiple testing was performed per outcome parameter.
Results
Subjects
In total, thirty-four subjects met the in- and exclusion criteria. Two subjects dropped out after the first test day due to personal circumstances. Therefore, thirty-two healthy volunteers (twenty-four female, age 25·3 (sd 3·8) years, BMI 22·5 (sd 1·9) kg/m2) completed the study protocol and were included in the analyses. No other adverse events were reported, and all subjects tolerated the interventions well.
Food intake
Based on estimated means, no differences in ad libitum food intake were observed after oral sham feeding with quinine, intragastric delivery of quinine or combined oral sham feeding with- and intragastric delivery of quinine v. placebo (placebo: 3273·6 (sem 131·8) kJ, oral sham feeding with quinine: 3072·7 (sem 132·2) kJ, intragastric delivery of quinine: 3289·0 (sem 132·6) kJ, oral sham feeding with- and intragastric delivery of quinine: 3204·1 (sem 133·1) kJ, P = 0·069) (Fig. 2). Furthermore, no trends in individual responses were found (Fig. 3).
Amount eaten in kJ (mean + sem) 50 min after oral placebo and intragastric placebo (OPGP), oral quinine and intragastric placebo (OQGP), oral placebo and intragastric quinine (OPGQ) and quinine both oral and intragastric (OQGQ). Based on an autoregressive (1) linear mixed model, no difference in food intake was observed between the conditions (P = 0·069). 
, OPGP, 
, OQGP, 
, OPGQ, 
, OQGQ.
Individual representation per subject of amount eaten in kJ (mean + sem) 50 min after oral placebo and intragastric placebo (OPGP), oral quinine and intragastric placebo (OQGP), oral placebo and intragastric quinine (OPGQ) and quinine both oral and intragastric (OQGQ). Based on an autoregressive (1) linear mixed model, no difference in food intake was observed between the conditions (P = 0·069).
Appetite sensations
The mean VAS scores for desire to eat, hunger, satiation and fullness are depicted in Fig. 4. Based on a linear mixed model, significant main effects of intervention were found for desire to eat and hunger scores, indicating an overall intervention effect on these scores. Post hoc pairwise comparisons showed a significant reduction in desire to eat and hunger scores for oral sham feeding with quinine v. placebo (both P < 0·001), intragastric delivery of quinine v. placebo (both P < 0·05), and oral sham feeding with quinine v. oral sham feeding with- and intragastric delivery of quinine (both P < 0·01). No main effects of intervention were found for satiation and fullness scores. No intervention × time interactions were found for any of the VAS scores; thus, intervention effects did not differ on specific time points.
Visual analogue scale (VAS) scores for desire to eat (a), hunger (b), satiation (c) and fullness (d) (mean + sem) before and after oral placebo and intragastric placebo (OPGP), oral quinine and intragastric placebo (OQGP), oral placebo and intragastric quinine (OPGQ) and quinine both oral and intragastric (OQGQ). Based on an autoregressive (1) linear mixed model, intervention effects were found for desire to eat and hunger scores (P < 0·001). Bonferroni correction was applied for post hoc pairwise comparisons. * P < 0·05, ** P < 0·01,*** P < 0·001. 
, OPGP, 
, OQGP, 
, OPGQ, 
, OQGQ.
Gastrointestinal complaints
The mean VAS scores for stomach pain, bloating and nausea are depicted in Fig. 5. No intervention effects for these VAS scores were found. Moreover, no intervention × time point interactions were found for these VAS scores.
Visual analogue scale (VAS) scores for stomach pain (a), bloating (b) and nausea (c) (mean + sem) before and after oral placebo and intragastric placebo (OPGP), oral quinine and intragastric placebo (OQGP), oral placebo and intragastric quinine (OPGQ) and quinine both oral and intragastric (OQGQ). Based on an autoregressive (1) linear mixed model, no differences were observed between conditions. , OPGP, , OQGP, , OPGQ, , OQGQ.
Heart rate variability
Heart rate and low-frequency:high-frequency ratio are depicted in Fig. 6. No intervention effects for these HRV measurements were found. Moreover, no intervention × time point interactions were found for these HRV measurements.
Heart rate variability (HRV) depicted by heart rate and low-frequency (LF):high-frequency (HF) ratio before and after oral placebo and intragastric placebo (OPGP), oral quinine and intragastric placebo (OQGP), oral placebo and intragastric quinine (OPGQ) and quinine both oral and intragastric (OQGQ). Based on an autoregressive (1) linear mixed model, no differences were observed between conditions. , OPGP, , OQGP, , OPGQ, , OQGQ.
Discussion
Our results show that food intake is affected neither by oral sham feeding of quinine, nor intragastric delivery of quinine, nor synchronous oral sham feeding and intragastric delivery of quinine compared with placebo. Moreover, no differences have been found in VAS scores for satiation or fullness and HRV measurements. However, VAS scores for desire to eat and hunger decreased significantly after oral sham feeding and intragastric delivery of quinine.
To the best of our knowledge, the effects of oral sham feeding with (bitter) tastants have not been described in literature previously. Moreover, the effects of bitter tastants on eating behaviour have been conducted only in small-sized studies. This is the first study to investigate the acute effects of a bitter tastant on eating behaviour in an adequately sized study.
The results of studies on the effects of bitter tastants on food intake, appetite sensations and GI peptides are not conclusive. Most studies reported only a trend towards a decrease in food intake after intragastric or intraduodenal delivery of bitter tastants(Reference van Avesaat, Troost and Ripken16,Reference Deloose, Janssen and Corsetti29–Reference Bitarafan, Fitzgerald and Little32) . Some studies, however, reported a statistically significant reduction in food intake(Reference Andreozzi, Sarnelli and Pesce33,Reference Iven, Biesiekierski and Zhao34) . In one study, no initial effect of encapsulated bitter compounds on food intake was observed, while over the day a significant decrease in food intake was found(Reference Mennella, Fogliano and Ferracane35). Deloose et al. (Reference Deloose, Janssen and Corsetti29) showed a longer sustained satiety effect after a standardised meal when the meal was preceded by intragastric administration of denatonium benzoate. Taken together, these results indicate that delivery of bitter tastants in the presence of, or followed by a energetic content, exerts a more pronounced effect on eating behaviour. With respect to our study, it is possible that a more marked decrease in food intake could have been found if food intake was measured over the course of the day. However, our aim was to explore in detail the acute effects of oral sham feeding and/or intragastric delivery of the bitter tastants quinine on energetic intake during the next meal and not over a longer period.
Intragastric administration of bitter compounds (quinine and denatonium benzoate) has been shown to reduce antral motility(Reference Deloose, Janssen and Corsetti29,Reference Deloose, Corsetti and Van Oudenhove36) and to decrease systemic motilin and ghrelin levels(Reference Deloose, Janssen and Corsetti29,Reference Iven, Biesiekierski and Zhao34,Reference Deloose, Corsetti and Van Oudenhove36) , whereas effects of bitter compounds on overall gastric emptying rate have not been demonstrated(Reference Deloose, Janssen and Corsetti29,Reference Bitarafan, Fitzgerald and Little32,Reference Andreozzi, Sarnelli and Pesce33,Reference Little, Gupta and Case37) . However, the effects of GI delivery of tastants on circulating GI peptide levels have not been fully elucidated. Several studies did not observe any changes in glucagon-like peptide-1, polypeptide YY and/or cholecystokinin(Reference van Avesaat, Troost and Ripken16,Reference Bitarafan, Fitzgerald and Little30,Reference Bitarafan, Fitzgerald and Little32) . In one study, an increase in plasma cholecystokinin was observed after intraduodenal delivery of the bitter tastant quinine, but systemic ghrelin levels were not affected(Reference Andreozzi, Sarnelli and Pesce33).
Where systemic GI peptide levels are considered to be an objective parameter to predict prospective food intake, VAS scores for appetite sensations can give insight in subjective feelings relating to prospective food intake. In the present study, oral sham feeding or intragastric delivery of quinine decreased the desire to eat and hunger sensations compared with placebo. Interestingly, there seems to be an overall trend of an upward slope for appetite throughout the test day. In this study, subjects were provided with the test meal around noon. Therefore, this might reflect the natural tendency to get an increased appetite towards habitual time of meal intake, due to conditioned hunger(Reference van den Akker, Havermans and Jansen38). Important to note is that synchronous oral sham feeding with- and intragastric delivery of quinine did not alter desire to eat and hunger scores compared with placebo. This rather unexpected finding could be explained by the higher starting point for this intervention, influencing a possible overall intervention effect.
Contrary to desire to eat and hunger sensations, satiation and fullness sensations were not affected. Since there was no intervention effect on actual food intake, this raises the question whether actual food intake might be more dependent on satiation and fullness rather than desire to eat and hunger. In addition, energetic intake might be influenced by a large array of different sensations and factors that are not necessarily captured by a single VAS score. Various studies that did find a significant decrease in food intake after GI delivery of tastants showed mixed results on VAS scores for appetite sensations. Iven et al. (Reference Iven, Biesiekierski and Zhao34) showed a decrease in hunger and an increase in satiety and fullness. Van Avesaat et al. (Reference van Avesaat, Troost and Ripken16) found a decrease in desire to eat and hunger and an increase in satiety, but no effects on fullness. Andreozzi et al. found no differences in satiation or desire to eat scores(Reference Andreozzi, Sarnelli and Pesce33). It must be noted that in the present study, no intervention × time interaction was found and therefore conclusions on timing of the effect of oral sham feeding with- and/or intragastric delivery of quinine on appetite sensations cannot be drawn. Moreover, interpretation of VAS scores for appetite sensations should always be done with care, since this usually is a secondary outcome parameter in studies on food intake and most studies might not have been adequately powered for such outcomes – as is the case for our study.
A strength of the design of the present study is the large sample size when compared with other research in the field. Moreover, possible inter-subject confounding factors (i.e. habitual meal size, daily energy requirements) were countered by the crossover design. However, this study also has several limitations. A limitation of this study is generalisability to daily life. In this study, subjects consumed their test meal without external stimuli (i.e. telephone use, watching television) and were asked to stop eating when comfortably full. In daily life, people might not be focused on their appetite sensations and be distracted by said external stimuli, which are known to have an increasing effect on eating behaviour(Reference Boulos, Vikre and Oppenheimer39,Reference Ogden, Coop and Cousins40) . However, before implementing interventions in daily life, their effects should first be investigated under controlled conditions, as was done in the present study. Another important limitation of this study is that systemic GI peptide levels were not assessed. Measurement of GI peptides could have provided a more complete overview of the effect of oral sham feeding with- and/or intragastric delivery of quinine on eating behaviour. However, a previous study from our group showed a decrease in food intake and increase in satiation without marked changes in systemic GI peptide levels(Reference van Avesaat, Troost and Ripken16). Although in vitro stimulation of intestinal cell lines with tastants results in markedly increased levels of GI peptides, these results have not always been reproduced in vivo, as stated above. It should be noted that all studies measured plasma levels of GI peptides, in search for systemic effects. It remains to be determined what the effect of GI delivery of tastants is on local splanchnic excretion of GI peptides or on possible paracrine effects. Measurement of local levels of GI peptides requires complex invasive techniques. We focused on other, non-invasive, markers that can indicate a shift in hunger/satiation, such as the balance in ANS, which can occur before systemic GI peptide changes can be detected(Reference Nederkoorn, Smulders and Jansen19,Reference Mattes20) and used HRV measurements(23).
In the present study, no differences in HRV measurements were observed between various interventions, which is in line with the fact that there was no shift in hunger/satiation, as indicated by the VAS scores for fullness and satiation. Moreover, food intake was not influenced by the various interventions. A recent meta-analysis showed that HRV is sensitive to changes in the ANS as a response to stress(Reference Kim, Cheon and Bai41). Although two studies showed meal intake to influence HRV(Reference Harthoorn and DransWeld42,Reference Sauder, Johnston and Skulas-Ray43) , it is uncertain whether HRV measurements are sensitive enough to detect satiation responses. Therefore, future studies should ascertain whether the application of HRV measurements in detecting satiation responses has an added value.
Furthermore, it has to be noted that the ideal interval between tastant delivery and the timing of the ad libitum test meal is unknown. In the present study, we employed a timing identical to that of studies from other groups investigating the effects of bitter compounds on food intake(Reference Deloose, Janssen and Corsetti29,Reference Bitarafan, Fitzgerald and Little30,Reference Andreozzi, Sarnelli and Pesce33) . However, these studies investigated only intragastric or intraduodenal effects of bitter tastants. It is possible that effects of oral sham feeding with quinine could have been found if the test meal was offered sooner after the intervention, since tasting a substance orally might have more acute effects. Moreover, our results suggest a fast response on desire to eat and hunger scores after intervention which could have driven the overall effect that was found. It is possible that earlier presentation of the test meal would have resulted in a reduction in energy intake after administration of quinine. On the other hand, the possibility of an increase in energy intake, due to the need to quell their symptoms (i.e. get rid of the bad taste of quinine), cannot be excluded. Future research protocols should consider timing as a factor to be investigated.
Another important aspect to mention is the dosage of quinine. According to the code of federal regulations stated by the United States Food and Drug Administration, soft drinks such as tonic water are allowed to contain eighty-three parts per million quinine(44). In this protocol, we chose to administer 75 mg of quinine-hydrochloride which is lower than this amount and aligns with previous studies conducted by our group(Reference van Avesaat, Troost and Ripken16,Reference Klaassen, Alleleyn and van Avesaat17) . Due to this relatively low dosage of quinine, should we have found significant effects on eating behaviour, this dosage of quinine could have been easily implemented for daily intake. Other studies employ various dosages of quinine administration ranging from 18 to 600 mg(Reference Deloose, Janssen and Corsetti29,Reference Bitarafan, Fitzgerald and Little30,Reference Bitarafan, Fitzgerald and Little32–Reference Iven, Biesiekierski and Zhao34,Reference Deloose, Corsetti and Van Oudenhove36) . The higher dosages may give rise to medical problems when implemented for daily intake. A systematic review on the usage of quinine as treatment for muscle cramps showed an increase in minor adverse events such as GI complaints, headache and tinnitus after daily intake of 200–500 mg for 3 d up to several weeks(Reference El-Tawil, Al Musa and Valli45). This aspect should also be considered when investigating the effects on eating behaviour of higher dosages of quinine.
Up to now, most studies investigating the effects of tastants on food intake focused on acute effects in single test meals. Repetitive or chronic administration of tastants has not been investigated, warranting studies to be conducted on long-term effects of tastants on energy intake.
In conclusion, we have shown that oral sham feeding with- or intragastric delivery of the bitter tastant quinine decreased desire to eat and hunger feelings, without affecting food intake, feelings of satiation and fullness, and HRV when compared with placebo.
Acknowledgements
We thank all the volunteers for participating in this study.
This research received no specific grant from any funding agency, commercial or not-for-profit sectors. Affiliation 1 is supported by the Province of Limburg, The Netherlands.
The authors’ responsibilities were as follows: formulating research questions: T. K., D. K., A. B., A. A. M. M. and F. J. T.; designing the study: T. K., D. K., A. M. E. A., E. W., A. B., A. A. M. M. and F. J. T.; investigation: T. K. and A. M. E. A.; data analysis: T. K.; writing-original draft preparation: T. K.; writing review and editing: T. K., A. M. E. A., E. W., D. K., A. A. M. M. and F. J. T.
The researchers were previously involved in an investigator-initiated study on a similar topic(Reference Klaassen, Alleleyn and van Avesaat17) for which Will Pharma SA received governmental funding (Subsidie MKB Innovatiestimulering Topsectoren, MIT) and covered all relevant costs related to the execution of that study. T. K. received a salary from Will Pharma SA as part of the ‘Subsidie MKB Innovatiestimulering Topsectoren’ (MIT) for the period related to the execution of that study(Reference Klaassen, Alleleyn and van Avesaat17). D. K. and A. A. M. M. have received an unrestricted grant from Will Pharma SA for the execution of a study unrelated to the present study (peppermint oil in IBS). D. K. and A. A. M. M. have received grants from Zon MW, The Netherlands Organisation for Health Research and Development, to evaluate efficacy of peppermint oil in IBS, hypnotherapy in IBS, and the efficacy of nortriptyline in functional dyspepsia. D. K. and A. A. M. M. have received research funding from Allergan and Grünenthal on IBS topics. D. K. has received research funding from the Dutch Foundation for Gastroenterology (Maag-Lever-Darmstichting) for IBS and United Europe Gastroenterology (UEG) for faecal incontinence. A. A. M. M. has given scientific advice to Bayer (topic: IBS), to Kyowa Kirin (topic: constipation), and to Takeda (topic: gastroparesis). A. A. M. M. received funding from Pentax Europe GmbH. A. A. M. M. has received funding from the Dutch Cancer Society related to endoscopy and to colorectal polyps. A. M. E. A., E. W., A. B., and F. J. T. reported no conflicts of interest.
Open access
